Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.143
Sell
RSI(14)
34.902
Neutral
STOCH(KDJ)(9,3,3)
29.089
Neutral
ATR(14)
0.577
Low Volatility
CCI(14)
-89.684
Neutral
Williams %R
77.024
Sell
TRIX(12,20)
-1.303
Sell
StochRSI(14)
63.435
Sell
Search
Edesa Biotech Inc
EDSAAdd to Watchlist
5.110USD
-0.140-2.67%
Close 07-31 16:00（ET）Quotes delayed by 15 min
49.23MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey ChartIntraday
1m
30m
1h
D
W
M
D
Today
-2.67%
5 Days
-2.67%
1 Month
-37.15%
6 Months
+336.75%
Year to Date
+259.86%
1 Year
+127.11%
Key Figures
5.260Open
5.290High
58.63KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
0.66%Turnover Ratio
5.250Prev. Close
4.770Low
141.85KTurnover
LossP/E Static
24.92P/B
0.00%Div Yield TTM
-72.43%ROA
20.32052wk High
0.67Volume Ratio
-6.17MNet Profit
8.89MShares
-1.3057EPS TTM
1.11Beta
-255.48%ROE
0.72052wk Low
9.90%Amplitude
--Gross Margin
49.23MMarket Cap
-2.69Reward/Risk
11.17%Risk Rate
TradingKey Stock Score of Edesa Biotech Inc
Currency: USD Updated: 2026-07-31Key Insights
Edesa Biotech Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 115 out of 385 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 15.00.In the medium term, the stock price is expected to trend down.Despite a very weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Edesa Biotech Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Edesa Biotech Inc Highlights
StrengthsRisks
Edesa Biotech, Inc. is a clinical-stage biopharmaceutical company developing ways to treat inflammatory and immune-related diseases. The Company’s clinical pipeline is focused on two therapeutic areas: medical dermatology and respiratory. In medical dermatology, the Company is developing EB06, an anti-CXCL10 monoclonal antibody candidate, as a therapy for vitiligo, a common autoimmune disorder that causes skin to lose its color in patches. Its medical dermatology assets also include EB01 (1.0% daniluromer cream), a Phase III-ready asset developed for use as a potential therapy for moderate-to-severe chronic allergic contact dermatitis (ACD), a common occupational skin condition. The Company’s advanced respiratory drug candidate is EB05 (paridiprubart), which is being evaluated in a United States government-funded platform study as a treatment for acute respiratory distress syndrome.
Undervalued
The company’s latest PE is -3.91, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 4.36M shares, increasing 23.32% quarter-over-quarter.
Held by Steven Cohen
Star Investor Steven Cohen holds 1.31 shares of this stock.
Analyst Rating
Based on
3
analysts
Buy
Current Rating
15.000
Target Price
+179.85%
Upside Space
Edesa Biotech Inc News
More news coming soon, stay tuned...
Earnings Forecast
Analyst Rating
Based on
3
analysts
Buy
Current Rating
15.000
Target Price
+179.85%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
496
Total
6
Median
7
Average
Company name
Ratings
Analysts
Edesa Biotech Inc
EDSA
3
Beigene Ltd
ONC
27
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
Ionis Pharmaceuticals Inc
IONS
25
Insmed Inc
INSM
23
1
2
3
...
99
Indicators
Moving Average
Indicators
Value
Direction
MA5
5.208
Sell
MA10
5.448
Sell
MA20
6.204
Sell
MA50
6.891
Sell
MA100
8.022
Sell
MA200
4.914
Buy
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Edesa Biotech Inc Info
Edesa Biotech, Inc. is a clinical-stage biopharmaceutical company developing ways to treat inflammatory and immune-related diseases. The Company’s clinical pipeline is focused on two therapeutic areas: medical dermatology and respiratory. In medical dermatology, the Company is developing EB06, an anti-CXCL10 monoclonal antibody candidate, as a therapy for vitiligo, a common autoimmune disorder that causes skin to lose its color in patches. Its medical dermatology assets also include EB01 (1.0% daniluromer cream), a Phase III-ready asset developed for use as a potential therapy for moderate-to-severe chronic allergic contact dermatitis (ACD), a common occupational skin condition. The Company’s advanced respiratory drug candidate is EB05 (paridiprubart), which is being evaluated in a United States government-funded platform study as a treatment for acute respiratory distress syndrome.
Ticker SymbolEDSA
CompanyEdesa Biotech Inc
CEONijhawan (Pardeep)
Websitehttps://www.edesabiotech.com/
Shareholders
Related Instruments
-0.53%
+0.27%
-2.51%
+0.32%
-1.45%
-0.92%
-0.64%
-0.82%
-8.79%
+0.52%
+0.68%
-0.95%
-0.71%
+0.44%
-1.08%
+3.29%
0.00%
-0.90%
+1.30%
-2.15%Popular Instruments
52378.000
+109.000 (+0.21%)
28160.900
-37.600 (-0.13%)
7475.100
+30.800 (+0.41%)
14749.000
-90.000 (-0.61%)
62852.000
-742.000 (-1.17%)
6365.400
-1.000 (-0.02%)
85.934
+2.764 (+3.32%)
308.910
-24.520 (-7.35%)
200.750
+5.710 (+2.93%)
4041.430
-61.400 (-1.50%)
FAQs
What is the current price of Edesa Biotech Inc (EDSA)?
The current price of Edesa Biotech Inc (EDSA) is 5.16.
What is the symbol of Edesa Biotech Inc?
The ticker symbol of Edesa Biotech Inc is EDSA.
What is the 52-week high of Edesa Biotech Inc?
The 52-week high of Edesa Biotech Inc is 20.32.
What is the 52-week low of Edesa Biotech Inc?
The 52-week low of Edesa Biotech Inc is 0.72.
What is the market capitalization of Edesa Biotech Inc?
The market capitalization of Edesa Biotech Inc is 45.81M.
Is Edesa Biotech Inc (EDSA) currently rated as Buy, Hold, or Sell?
According to analysts, Edesa Biotech Inc (EDSA) has an overall rating of Buy, with a price target of 15.00.
What is the Earnings Per Share (EPS TTM) of Edesa Biotech Inc (EDSA)?
The Earnings Per Share (EPS TTM) of Edesa Biotech Inc (EDSA) is -1.27.